Effect | None |
Trial Design | Double blind |
Trial Length | 6+ Months |
Number of Subjects | 29 |
Sex | Both Genders |
Age Range | 30-44 |
Supplementation of 10mg riboflavin daily over the course of six months in subjects with multiple sclerosis failed to influence the disease state any differently than placebo (both groups experienced benefit) and also failed to have an influence on homocysteine concentrations in serum or glutathione reductase activity in red blood cells.